EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity

Peng Liu, Jia Guo, Zuozhong Xie, Yusheng Pan, Benliang Wei, Ying Peng, Shuo Hu, Jinsong Ding, Xiang Chen, Juan Su, Hong Liu, Wenhu Zhou iD

Advanced Science · 2025-02 · 12 (7)

DOI: 10.1002/advs.202410545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.12.2024. Verfasst von Peng Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China. Hauptthemen laut MEDLINE: Calcium Phosphates, Nanoparticles, Melanoma, Immunotherapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Key Program of National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma, a malignant skin tumor, presents significant treatment challenges, particularly in unresectable and metastatic cases. While immune checkpoint inhibitors (ICIs) targeting PD‐1/PD‐L1 have brought new hope, their efficacy is limited by low response rates and significant immune‐mediated adverse events (irAEs). Through multi‐omics data analysis, it is discovered that the spatial co‐localization of CD73 and PD‐L1 in melanoma correlates with improved progression‐free survival (PFS), suggesting a synergistic potential of their inhibitors. Building on these insights, a novel therapeutic strategy using calcium phosphate (CaP) nanoparticles is developed for the co‐delivery of aPD‐L1 and APCP, a CD73 inhibitor. These nanoparticles, constructed via a biomineralization method, exhibit high drug‐loading capacity and pH‐responsive drug release. Compared to free aPD‐L1, the CaP‐delivered aPD‐L1 effectively avoids systemic side effects while significantly enhancing anti‐tumor efficacy, surpassing even a 20‐fold dose of free aPD‐L1. Furthermore, the co‐delivery of aPD‐L1 and APCP via CaP nanoparticles demonstrates a synergistic anti‐tumor effect, with substantial immune activation and prevention of tumor recurrence through immune memory effects. These findings suggest that the co‐delivery of aPD‐L1 and APCP using CaP nanoparticles is a promising approach for improving melanoma immunotherapy, achieving enhanced efficacy and reduced toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium PhosphatesNanoparticlesMelanomaImmunotherapy5'-NucleotidaseB7-H1 AntigenSkin NeoplasmsAnimalsMiceHumansCell Line, TumorImmune Checkpoint InhibitorsFemale

Stichwörter der Autor:innen

biomineralizationdrug deliveryimmune checkpoint inhibitorsmelanomasynergistic therapytumor targeting

Substanzen

Calcium Phosphatescalcium phosphate5'-NucleotidaseB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Key Laboratory of Biological Nanotechnology, Changsha, Hunan, 410008, China.
  • Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, 410008, China.
  • Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, Hunan, 410008, China.

ORCID-Profile: Wenhu Zhou

Förderung

  • National Key Research and Development Program of China
  • Key Program of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Science Found for Creative Research Groups of the National Natural Science Foundation of China
  • Science and Technology Innovation Program of Hunan Province
  • Central South University Research Program of Advanced Interdisciplinary Studies
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Hunan Province in China

Zitieren

APA

Liu, P., Guo, J., Xie, Z., Pan, Y., Wei, B., Peng, Y., Hu, S., Ding, J., Chen, X., Su, J., Liu, H., & Zhou, W. (2025). Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity. Advanced Science, 12(7). https://doi.org/10.1002/advs.202410545

Vancouver

Liu P, Guo J, Xie Z, Pan Y, Wei B, Peng Y, et al. Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity. Advanced Science. 2025;12(7). doi:10.1002/advs.202410545

BibTeX
@article{Liu2025,
  author = {Liu, Peng and Guo, Jia and Xie, Zuozhong and Pan, Yusheng and Wei, Benliang and Peng, Ying and Hu, Shuo and Ding, Jinsong and Chen, Xiang and Su, Juan and Liu, Hong and Zhou, Wenhu},
  title = {Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {7},
  doi = {10.1002/advs.202410545}
}
Kostenlos starten →